{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:02:04Z","timestamp":1784523724136,"version":"3.55.0"},"reference-count":8,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2026.1909842","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:20:37Z","timestamp":1784521237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary: Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Toufic","family":"Eid","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Al-Bitar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1843032","article-title":"Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy","volume":"16","author":"Cifuentes-Quin","year":"2026","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00544-7","article-title":"Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy","volume":"23","author":"Martin","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e18842","DOI":"10.1097\/MD.0000000000018842","article-title":"Subsequent risk of acute urinary retention and androgen deprivation therapy in patients with prostate cancer: a population-based retrospective cohort study","volume":"99","author":"Yang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18535","DOI":"10.1038\/s41598-022-21963-1","article-title":"Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy","volume":"12","author":"Bang","year":"2022","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.03.041","article-title":"The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors","volume":"64","author":"Kopp","year":"2013","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70084-0","article-title":"Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care","volume":"13","author":"Zumsteg","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:20:38Z","timestamp":1784521238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":8,"alternative-id":["10.3389\/fonc.2026.1909842"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1909842","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1909842"}}